跳至主要内容
临床试验/NCT04706208
NCT04706208已完成不适用

Identifying Body Awareness-related Brain Network Changes During Cognitive Multisensory Rehabilitation for Reduced Neuropathic Pain in People With Spinal Cord Injury

University of Minnesota2 个研究点 分布在 1 个国家目标入组 58 人开始时间: 2020年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
58
试验地点
2
主要终点
Pain Numeric Rating Scale (NPRS) - part of the International SCI Basic Pain Data Set

研究概览

简要总结

Many adults with spinal cord injury (SCI) suffer from long-term debilitating neuropathic pain. Available treatments, including opioids, are ineffective at eliminating this pain. Based on preliminary data from Dr Morse and from Dr Van de Winckel, we have demonstrated that brain areas that are important for body awareness and pain perception (parietal operculum, insula) have weaker brain connectivity in adults with spinal cord injury than in able-bodied healthy adults and that Cognitive Multisensory Rehabilitation (CMR) can restore these networks. This study uses a cross-over study for adults with SCI and a comparison of baseline outcomes in adults with SCI vs able-bodied healthy adults to address two aims:

AIM 1: Determine baseline differences in resting-state and task-based fMRI activation and connectivity in adults with SCI compared to able-bodied healthy controls.

AIM 2: Identify changes in brain activation and connectivity, as well as behavioral outcomes in pain and body awareness in adults with SCI after CMR versus standard of care.

详细描述

One of the reasons for the current lack of effective therapies is that underlying mechanisms of neuropathic pain after SCI are not yet fully understood. Nonetheless, as suggested by numerous studies, because of the spinal injury, the inflow of sensory information is dramatically altered. Therefore, the brain is missing sensory information or receiving incorrect sensory information, which may alter the brain circuitry related to pain sensation, which in turn may drive the perception of neuropathic pain.

Cognitive multisensory rehabilitation (CMR), developed for motor recovery after stroke, has shown to be effective for treating adults with chronic pain, i.e., after shoulder impingement when compared to traditional physical therapy; or in a case study of severe phantom limb pain after below the knee amputation, resulting in such substantial pain reduction that the patient could finally be fitted with a prosthesis and walk. CMR is thought to be effective because it restores mental body representations by recalibrating sensations in combination with a focus on body awareness. Body awareness is often impaired in people with chronic pain and with dysfunctions in the sensory and motor networks, such as after SCI.

This study uses a cross-over study for adults with SCI and a comparison of baseline outcomes in adults with SCI vs able-bodied healthy adults to address two aims:

AIM 1: Determine baseline differences in resting-state and task-based fMRI activation and connectivity in adults with SCI compared to able-bodied healthy controls.

AIM 2: Identify changes in brain activation and connectivity, as well as behavioral outcomes in pain and body awareness in adults with SCI after CMR versus standard of care.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • SCI participants:
  • SCI of ≥ 3months
  • medically stable with paraplegia (ASIA grade A-C, who can self-transfer with some assistance)
  • neuropathic pain (>3 on the numeric pain rating scale)
  • Able-bodied participants:
  • sex and age matched
  • healthy, able-bodied

排除标准

  • MRI contra-indications (stabilizing hardware is typically MRI safe) including seizures, cognitive impairment, or other major medical complications

结局指标

主要结局

Pain Numeric Rating Scale (NPRS) - part of the International SCI Basic Pain Data Set

时间窗: weekly during the two intervention periods (each 12 weeks)

The numeric pain rating scale assesses the highest, lowest and average pain ratings over the past week. The 1-10 numerical pain rating scale has been recommended by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) consensus group for use in pain clinical trials and by the 2006 National Institute on Disability and Rehabilitation Research (NIDRR) SCI Pain outcome measures consensus group. This scale is recommended to standardize pain outcomes across studies.

次要结局

  • Physical Activity Recall Questionnaire(baseline - mid evaluation (after 12 weeks) - final evaluation (after second period of 12 weeks))
  • Pittsburgh Sleep Quality Index (PSQI)(baseline - mid evaluation (after 12 weeks) - final evaluation (after second period of 12 weeks))
  • Spielberger State-Trait Anxiety Inventory(baseline - mid evaluation (after 12 weeks) - final evaluation (after second period of 12 weeks))
  • Patient Health Questionnaire (PHQ-9)(baseline - mid evaluation (after 12 weeks) - final evaluation (after second period of 12 weeks))
  • Moorong Self-Efficacy Scale (MSES)(baseline - mid evaluation (after 12 weeks) - final evaluation (after second period of 12 weeks))
  • WHOQOL-BREF(baseline - mid evaluation (after 12 weeks) - final evaluation (after second period of 12 weeks))
  • Revised Body Awareness Rating Questionnaire (BARQ)(baseline - mid evaluation (after 12 weeks) - final evaluation (after second period of 12 weeks))
  • Tampa Scale For Kinesiophobia(baseline - mid evaluation (after 12 weeks) - final evaluation (after second period of 12 weeks))
  • Physical Activity Enjoyment Scale (PACES)(baseline - mid evaluation (after 12 weeks) - final evaluation (after second period of 12 weeks))
  • Patient Specific Functional Scale(baseline - mid evaluation (after 12 weeks) - final evaluation (after second period of 12 weeks))
  • International SCI Basic Pain Data Set(baseline - mid evaluation (after 12 weeks) - final evaluation (after second period of 12 weeks))

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Identifying Body Awareness-related Brain Network... | 临床试验